US Merger & Acquisition SEC Filings — June 11, 2026

11-06-2026

Copley Acquisition Corp (NYSE: COPL) announced a definitive business combination agreement with Ignite Proteomics, a leader in pathway-level protein analytics for precision oncology. The combined entity will be named Ignite Proteomics Holdings, Inc. and will list on the NYSE at a pro forma enterprise value of $150 million. The transaction is expected to close in the second half of 2026, subject to customary conditions and shareholder approvals.

• · Copley is a SPAC that went public via an IPO on December 19, 2023.
• · Ignite's current commercial focus is in breast cancer, with plans to expand into other tumor types.
• · Clear Street LLC acted as financial advisor to Copley; Ladenburg Thalmann & Co. Inc. acted as financial advisor to Ignite.
• · The transaction is subject to adoption by Copley shareholders and Ignite members, as well as other customary closing conditions.

11-06-2026

Mountain Lake Acquisition Corp. (MLAC) announced the consummation of its business combination with Avalanche Treasury Corporation (AVAT) on June 11, 2026. The combined company's Class A common stock will begin trading on Nasdaq under the ticker symbol 'AVAT' on the same day. The transaction was approved by MLAC shareholders on June 4, 2026, and all closing conditions have been satisfied or waived. No financial terms of the deal were disclosed in the filing.

• · The business combination was approved by MLAC shareholders at an extraordinary general meeting on June 4, 2026.
• · MLAC was a blank check company (SPAC) formed for the purpose of effecting a merger or similar business combination.
• · AVAT provides investors with exposure to the Avalanche ecosystem without directly holding digital assets.
• · BTIG, LLC served as financial and capital markets advisor to MLAC.
• · The combined company will trade under the ticker 'AVAT' on Nasdaq.

11-06-2026

Melar Acquisition Corp. I (MACIU) entered into a promissory note agreement with its sponsor, Melar Acquisition Sponsor I LLC, for up to $1.5 million to fund working capital needs prior to its proposed initial business combination. The note carries a high 17.5% annual interest rate, with $223,079.12 already advanced. The principal and interest are due upon the earlier of the business combination closing or the company's liquidation, and up to $1.5 million of unpaid amounts may be converted into warrants at the payee's option.

• · The note is unregistered under the Securities Act of 1933 and may not be sold or transferred without registration or a legal opinion.
• · Interest is compounded annually at 17.5%.
• · Drawdowns require a written request and must be funded within five business days; the maximum aggregate drawdown is $1.5 million.
• · Upon an event of default (e.g., failure to pay within one business day of maturity, voluntary/involuntary bankruptcy), the entire unpaid amount becomes immediately due.
• · The payee waives any claim to the trust account established from the IPO proceeds and agrees not to seek recourse against it.
• · Conversion option: at the payee's election, up to $1.5 million of unpaid principal and interest may be converted into warrants to purchase Class A ordinary shares at $1.00 per warrant, identical to the private placement warrants from the IPO.
• · Holders of conversion warrants are entitled to one demand registration and piggyback registration rights under the existing Registration Rights Agreement dated June 17, 2024.
• · The note is governed by Delaware law.

11-06-2026

Tribeca Strategic Acquisition Corp. consummated its IPO of 14,000,000 units at $10.00 per unit on June 1, 2026, generating gross proceeds of $140,000,000, and simultaneously completed a private placement of 470,000 units for $4,700,000. A total of $140,350,000 was placed in a trust account. However, the company's audited balance sheet reveals a shareholders' deficit of $4,687,689 and the independent auditor has raised substantial doubt about the company's ability to continue as a going concern due to insufficient cash and working capital to sustain operations for one year.

• · The company is a blank check company incorporated on October 15, 2025, focusing on software, technology, AI, digital assets, clean energy, and other high-growth sectors.
• · BTIG, LLC has not exercised its 45-day option to purchase up to an additional 2,100,000 units for over-allotments as of the filing date.
• · Transaction costs include $2,800,000 cash underwriting fees, $4,900,000 deferred underwriting fees, and $1,194,202 other offering costs.
• · The trust account holds $140,350,000, which includes up to $4,900,000 of deferred underwriting commissions.
• · The company has an accumulated deficit of $4,687,287 and total shareholders' deficit of $4,687,689.
• · The auditor's report includes a going concern emphasis, noting insufficient cash and working capital to sustain operations for one year from the balance sheet date.

11-06-2026

Bowen Acquisition Corp (BOWN) has amended its Articles of Association to extend the deadline to complete an initial business combination from June 14, 2026, to December 31, 2026, if the Board determines a delay is necessary. The amendment also provides for a mandatory liquidation and redemption of public shares at trust account value (plus interest, less up to $100,000 for liquidation expenses) if no deal is consummated by the extended deadline. This extension gives the company additional time to pursue a merger target but also signals that a timely completion of a business combination was not previously assured.

• · The original deadline to consummate a Business Combination was June 14, 2026.
• · The Board may unilaterally extend the deadline to December 31, 2026.
• · If no deal is completed by the extended deadline, the company must cease operations, redeem public shares from the Trust Account within ten business days, and then liquidate.
• · Up to $100,000 of interest on Trust funds may be retained to cover liquidation expenses.
• · The amendment supersedes the previous version of Article 37.8 in the company's Articles of Association.

11-06-2026

Chiesi Group completed its acquisition of KalVista Pharmaceuticals on June 11, 2026, for $27.00 per share in cash, with approximately 77.8% of shares tendered. KalVista is now a wholly owned subsidiary of Chiesi, contributing its oral HAE treatment EKTERLY® (sebetralstat) to Chiesi's Rare Diseases unit. The transaction closed with the merger and delisting of KalVista's common stock from Nasdaq, but no financial performance metrics are provided in this filing.

• · EKTERLY is approved in the United States, United Kingdom, European Union, Japan, Switzerland, Australia, and Singapore for HAE attacks in patients 12 years and older.
• · Ongoing studies are exploring EKTERLY for HAE attacks in children aged 2 to 11.
• · Multiple regulatory applications for EKTERLY are under review in key global markets.
• · Chiesi is a certified B Corp since 2019 and aims to reach Net-Zero GHG emissions by 2035.
• · Chiesi has 31 affiliates worldwide and 6 R&D hubs outside of Parma.

11-06-2026

ZincFive, a nickel-zinc battery solutions provider for data centers and AI infrastructure, has agreed to go public via a business combination with SPAC Spark I Acquisition Corp (NASDAQ: SPKL) at a pre-money valuation of $600 million and pro forma enterprise value of $752 million. The transaction is expected to deliver at least $100 million in gross proceeds from a committed PIPE (fully satisfying the minimum cash condition) plus up to $25 million from Spark I's trust, with existing ZincFive shareholders rolling 100% of their equity. While ZincFive's revenue doubled from 2024 to 2025 to approximately $66.9 million and it has an $81 million backlog, the company's financials for 2024 and 2025 are preliminary and unaudited, and the transaction is subject to shareholder approval and regulatory review with a target close in the second half of 2026.

• · ZincFive's revenue doubled from 2024 to 2025 to approximately $66.9 million, but these figures are preliminary and unaudited.
• · The company has nearly 2 GW of systems shipped or under contract globally and an $81 million commercial backlog as of December 31, 2025.
• · The transaction includes a $35 million bridge loan facility, of which $28.5 million is expected to be repaid at closing.
• · The combined company will be named ZincFive, Inc. and trade on Nasdaq under ticker ZFIV.
• · The Boards of both companies have unanimously approved the transaction, which is expected to close in the second half of 2026.
• · Advisors include Cantor Fitzgerald (financial advisor and lead PIPE placement agent), Chardan (capital markets advisor), Cooley LLP (legal to ZincFive), Wilson Sonsini (legal to Spark I), and Latham & Watkins (legal to Cantor).

11-06-2026

YHN Acquisition I Ltd received a Nasdaq deficiency notice on June 10, 2026, for failing to meet the minimum total holders requirement of 400 holders (Listing Rule 5450(a)(2)). The company has 45 days to submit a compliance plan, with a possible extension of up to 180 days, and may alternatively apply to transfer to the Nasdaq Capital Market. There is no immediate impact on trading, but the company faces potential delisting risk if compliance is not regained.

• · The deficiency notice was received on June 10, 2026, and the company has 45 calendar days to submit a compliance plan.
• · If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the notice date.
• · The company may alternatively apply for a transfer to the Nasdaq Capital Market, which requires a $5,000 application fee and meeting Capital Market continued listing requirements.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.

11-06-2026

Adial Pharmaceuticals acquired Azora Therapeutics, gaining its lead asset AT177, a colon-targeted AhR agonist for ulcerative colitis. Concurrently, Adial secured a private placement of up to $64 million, with an initial $32 million upfront and potential additional $32 million upon Phase 1 initiation. The combined company expects to advance AT177 through IND-enabling studies and Phase 1 trials, with a proof-of-concept trial planned for 2027. However, existing Adial stockholders will be diluted to only 7.7% ownership post-transaction, and the company's historical focus on addiction treatments (AD04) is being deprioritized.

• · Azora was spun out of Stanford University's SPARK translational medicine program.
• · AT177 is a prodrug of indirubin, the most potent AhR agonist in indigo naturalis.
• · In preclinical studies, AT177 demonstrated robust local colonic AhR activation with markedly limited systemic exposure and superior colon-to-systemic selectivity compared to other AhR agonists.
• · The acquisition was structured as an asset acquisition; all of Azora's outstanding equity interests were exchanged for 437,474 shares of Adial common stock and approximately 12,930 shares of Series A non-voting convertible preferred stock (representing 12,930,617 common shares on an as-converted basis).
• · Adial stockholder approval is required for conversion of Series A preferred stock and exercisability of warrants; a stockholder meeting will be held promptly.
• · The private placement was led by Coastlands Capital with participation from Boxer Capital Management, Stonepine Capital Management, AuGC BioFund, and other biotech specialists and institutional investors along with insiders and management.
• · Adial's historical program AD04 is a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder in heavy drinking patients.